Financiere des Professionnels Fonds d investissement inc. Invests $1.10 Million in United Therapeutics Corporation $UTHR

Financiere des Professionnels Fonds d investissement inc. purchased a new position in United Therapeutics Corporation (NASDAQ:UTHR) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 1,849 shares of the biotechnology company’s stock, valued at approximately $1,096,000.

Several other hedge funds have also bought and sold shares of UTHR. Wellington Management Group LLP increased its stake in shares of United Therapeutics by 74.5% during the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after purchasing an additional 1,042,711 shares in the last quarter. Norges Bank purchased a new position in shares of United Therapeutics during the fourth quarter valued at approximately $293,418,000. Avoro Capital Advisors LLC boosted its position in shares of United Therapeutics by 17.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after purchasing an additional 383,838 shares in the last quarter. Janus Henderson Group PLC boosted its position in shares of United Therapeutics by 75.1% in the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after purchasing an additional 341,383 shares in the last quarter. Finally, Baillie Gifford & Co. purchased a new stake in shares of United Therapeutics in the 4th quarter worth approximately $157,390,000. Institutional investors own 94.08% of the company’s stock.

Insider Activity

In related news, CFO James Edgemond sold 10,000 shares of the stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $572.61, for a total transaction of $5,726,100.00. Following the sale, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $10,808,586.36. This trade represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders sold 564,743 shares of company stock worth $316,423,257 over the last 90 days. Corporate insiders own 8.60% of the company’s stock.

United Therapeutics Trading Up 1.3%

UTHR stock opened at $535.67 on Friday. The stock’s 50 day simple moving average is $552.38 and its 200 day simple moving average is $530.14. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $609.35. The stock has a market capitalization of $22.74 billion, a PE ratio of 19.77, a price-to-earnings-growth ratio of 1.77 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. During the same period in the previous year, the business posted $6.63 EPS. The firm’s revenue for the quarter was down 1.6% on a year-over-year basis. On average, research analysts predict that United Therapeutics Corporation will post 26.63 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on UTHR shares. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Bank of America reduced their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Raymond James Financial began coverage on United Therapeutics in a research report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price target for the company. Finally, Royal Bank Of Canada upped their price target on shares of United Therapeutics from $701.00 to $704.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. Ten equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $644.82.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.